Circular Peptide Particle Formation for Size and Shape Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing circular biologically active peptide particles lack sufficient control over size uniformity, shape selectivity, and skeletal density, making them difficult to produce efficiently and reproducibly.
Innovation Solution
A method involving the formation of droplets containing a peptide, followed by contacting with a second liquid and removing the liquids to form particles with up to 10% (w/w) peptide and circularity from 0.10 to 1.00, enhancing stability and control over particle properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional synthesis methods are used for circular peptide particles, then particle formation is achieved, but size uniformity, shape selectivity, and skeletal density control are insufficient
Solution Approach 1:
The synthesis process is divided into discrete steps: peptide assembly into circular structures, droplet formation with controlled size, and selective precipitation. This segmentation allows independent optimization of each step to achieve both precision and efficiency
Solution Approach 2:
The patent employs systematic variation of parameters including peptide concentration, solvent composition, temperature, and pH to precisely control particle size uniformity, shape, and skeletal density while maintaining manufacturing efficiency
2Manufacturing precision
If conventional synthesis methods are used for circular peptide particles, then particle formation is achieved, but shape selectivity and skeletal density control are insufficient
Solution Approach 1:
The patent applies local quality control by optimizing specific conditions for different stages: early-stage peptide assembly promotes circular morphology, while later-stage precipitation controls skeletal density, allowing precise shape selectivity without overwhelming process complexity
Solution Approach 2:
Peptide circular assembly is achieved preliminarily before particle formation, ensuring shape selectivity is established early in the process. This preliminary structuring simplifies subsequent steps and reduces overall process complexity
3Duration of action of stationary object
If peptide particles are stored without refrigeration, then stability and activity are maintained over extended periods
Solution Approach 1:
The patent utilizes phase transition from soluble peptide to precipitated particle form, creating a stable solid state that resists degradation. The controlled precipitation process produces particles with optimized crystallinity or amorphous structure that maintains peptide stability at ambient temperatures
Solution Approach 2:
The particles are designed as composite structures combining peptide with stabilizing excipients or forming peptide-peptide interactions that create a protective matrix, enhancing stability and extending storage duration without refrigeration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the production of stable, biologically active peptide particles that maintain activity over extended periods without refrigeration, suitable for pharmaceutical compositions and other applications.
Implementation Method 1
Recent advances in synthesis and the controlled assembly of bioactive particles have enabled their applications for use in therapy
Implementation Method 2
allowing the droplets to dry; and removing the first and second liquids, thereby forming particles comprising a peptide
Data Source
AI summary
The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles comprising biologically active peptides.